FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667789> ?p ?o ?g. }

• W4385667789 endingPage "e22273e7" @default.
• W4385667789 startingPage "e22273e7" @default.
• W4385667789 abstract "Topic: 22. Stem cell transplantation - Clinical Background: Consolidative strategy for high-risk acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) still relies on the curative effect of graft-versus-leukaemia(GVL) reaction following allogeneic stem cell transplant (allo-HSCT). Despite the improvement in the HLA tissue typing and mismatched unrelated donor transplants, a proportion of patients needing an allo-HSCT will still lack a donor and the debate on which alternative donor is most suitable is still active. Aims: Herein we report the outcome of patients affected with AML and MDS transplanted following haploidentical stem cell transplant (haplo-HSCT) at King’s College Hospital, London, between August 2010 and August 2021. Methods: Haplo-HSCT was performed using GCSF-mobilized peripheral blood stem cells(PBSC) as consolidative strategy for patients in complete morphological remission. Conditioning regimens were with cyclophosphamide 29mg/Kg, fludarabine 150mg/m2 and 200cGy Total Body Irradiation(FCTBI)or with thiotepa 10mg/Kg, fludarabine150 mg/m2, busulphan 9.6mg/kg (TBF). GVHD prophylaxis consisted of post-transplant cyclophosphamide(50 mg/kg day +3 and +4), mycophenolate and tacrolimus. Patients received FCTBI or TBF based on HCT-CI score and upper age limit of 65 for myeloablative conditioning. Probabilities of overall survival(OS) and GVHD-relapse-free survival (GRFS)was calculated using the Kaplan-Meier method.Relapse incidence(RI) and transplant-related mortality(TRM) rates were estimated using cumulative incidence(CI) functions and considered as competing risks.For GvHD, death and relapse were considered competing events. Statistical analyses were performed with GraphPad Prism Version9.4.1. Results: Forty patients with a median age of 50(range 21-69) and affected with high-risk myeloid malignancies were identified for this study (AML n=28, MDS n=12). Most patients(82%)received conditioning with FCTBI, and the remaining had TBF(18%). A median of 6.1x106 CD34+/Kg was infused(range3.37–14.26).Median time to neutrophil >1000/uL was 18days(13-42), and 25 days(14-44) to platelets>20.000/uL. Two cases of primary graft failure occurred. Median unfractionated, CD3+ and CD15 chimerism at 365days after transplant were 99%, 100% and 100% donor, respectively.One year and three years OS were62% and43%, respectively with a median OS of 22 months. One year and 3y GFRS were 47%and 34%, respectively. The global CI of relapse was 17%with a median time to relapse of 4 months(range 2-14). Incidence of acute GVHD was 22%(grade I/II);two cases of grade III were diagnosed. Chronic GVHD occurred in 17% of patients; moderate and severe cases were noted in 2 and 5 patients, respectively. TRM was37%, with a median time to TRM of 18 months(range 1-49). The main causes of death were infections(10 cases), GVHD(5 cases), disease progression(8 cases), and post-transplant lymphoproliferative disorder(1 case).CMV reactivation occurred in 50% of patients with a median time to first CMV reactivation of 46 days (range 13 – 415).No case of CMV disease occurred. Summary/Conclusion: This study shows that unmanipulated haplo-HSCT is a feasible and safe strategy for patients affected with high-risk AML and MDS.Despite the administration of reduced-intensity conditioning in most patients, the relatively low relapse rate is indirect proof of the curative effect of haplo-GVL. Our experience further confirms the safety of haplo-PBSC when the GVHD prophylaxis relies on post-transplant cyclophosphamide combined with mycophenolate and tacrolimus. Future efforts are needed to decrease the TRM mainly resulting from septic events due to the profound immune dysregulation and slow immune recovery following haplo-HSCT.Keywords: Haploidentical stem cell transplantation, Acute myeloid leukemia, Allogeneic bone marrow transplant" @default.
• W4385667789 created "2023-08-09" @default.
• W4385667789 creator A5007230365 @default.
• W4385667789 creator A5011143459 @default.
• W4385667789 creator A5015442636 @default.
• W4385667789 creator A5030102793 @default.
• W4385667789 creator A5043295492 @default.
• W4385667789 creator A5045018770 @default.
• W4385667789 creator A5047879915 @default.
• W4385667789 creator A5060691458 @default.
• W4385667789 creator A5061733081 @default.
• W4385667789 creator A5067660440 @default.
• W4385667789 creator A5073198334 @default.
• W4385667789 creator A5080214681 @default.
• W4385667789 creator A5081252933 @default.
• W4385667789 creator A5083878486 @default.
• W4385667789 creator A5088941351 @default.
• W4385667789 creator A5089005704 @default.
• W4385667789 creator A5092614147 @default.
• W4385667789 date "2023-08-01" @default.
• W4385667789 modified "2023-09-27" @default.
• W4385667789 title "P1288: UNMANIPULATED PERIPHERAL HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT IS AN EFFECTIVE CONSOLIDATIVE STRATEGY FOR HIGH-RISK ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROME" @default.
• W4385667789 doi "https://doi.org/10.1097/01.hs9.0000972040.22273.e7" @default.
• W4385667789 hasPublicationYear "2023" @default.
• W4385667789 type Work @default.
• W4385667789 citedByCount "0" @default.
• W4385667789 crossrefType "journal-article" @default.
• W4385667789 hasAuthorship W4385667789A5007230365 @default.
• W4385667789 hasAuthorship W4385667789A5011143459 @default.
• W4385667789 hasAuthorship W4385667789A5015442636 @default.
• W4385667789 hasAuthorship W4385667789A5030102793 @default.
• W4385667789 hasAuthorship W4385667789A5043295492 @default.
• W4385667789 hasAuthorship W4385667789A5045018770 @default.
• W4385667789 hasAuthorship W4385667789A5047879915 @default.
• W4385667789 hasAuthorship W4385667789A5060691458 @default.
• W4385667789 hasAuthorship W4385667789A5061733081 @default.
• W4385667789 hasAuthorship W4385667789A5067660440 @default.
• W4385667789 hasAuthorship W4385667789A5073198334 @default.
• W4385667789 hasAuthorship W4385667789A5080214681 @default.
• W4385667789 hasAuthorship W4385667789A5081252933 @default.
• W4385667789 hasAuthorship W4385667789A5083878486 @default.
• W4385667789 hasAuthorship W4385667789A5088941351 @default.
• W4385667789 hasAuthorship W4385667789A5089005704 @default.
• W4385667789 hasAuthorship W4385667789A5092614147 @default.
• W4385667789 hasBestOaLocation W43856677891 @default.
• W4385667789 hasConcept C120665830 @default.
• W4385667789 hasConcept C121332964 @default.
• W4385667789 hasConcept C126322002 @default.
• W4385667789 hasConcept C141071460 @default.
• W4385667789 hasConcept C143998085 @default.
• W4385667789 hasConcept C2776694085 @default.
• W4385667789 hasConcept C2776755627 @default.
• W4385667789 hasConcept C2777408962 @default.
• W4385667789 hasConcept C2778880498 @default.
• W4385667789 hasConcept C2779263901 @default.
• W4385667789 hasConcept C2779968505 @default.
• W4385667789 hasConcept C2780007613 @default.
• W4385667789 hasConcept C2780611847 @default.
• W4385667789 hasConcept C2780817109 @default.
• W4385667789 hasConcept C28328180 @default.
• W4385667789 hasConcept C2911091166 @default.
• W4385667789 hasConcept C54355233 @default.
• W4385667789 hasConcept C61511704 @default.
• W4385667789 hasConcept C71924100 @default.
• W4385667789 hasConcept C86803240 @default.
• W4385667789 hasConcept C88879693 @default.
• W4385667789 hasConceptScore W4385667789C120665830 @default.
• W4385667789 hasConceptScore W4385667789C121332964 @default.
• W4385667789 hasConceptScore W4385667789C126322002 @default.
• W4385667789 hasConceptScore W4385667789C141071460 @default.
• W4385667789 hasConceptScore W4385667789C143998085 @default.
• W4385667789 hasConceptScore W4385667789C2776694085 @default.
• W4385667789 hasConceptScore W4385667789C2776755627 @default.
• W4385667789 hasConceptScore W4385667789C2777408962 @default.
• W4385667789 hasConceptScore W4385667789C2778880498 @default.
• W4385667789 hasConceptScore W4385667789C2779263901 @default.
• W4385667789 hasConceptScore W4385667789C2779968505 @default.
• W4385667789 hasConceptScore W4385667789C2780007613 @default.
• W4385667789 hasConceptScore W4385667789C2780611847 @default.
• W4385667789 hasConceptScore W4385667789C2780817109 @default.
• W4385667789 hasConceptScore W4385667789C28328180 @default.
• W4385667789 hasConceptScore W4385667789C2911091166 @default.
• W4385667789 hasConceptScore W4385667789C54355233 @default.
• W4385667789 hasConceptScore W4385667789C61511704 @default.
• W4385667789 hasConceptScore W4385667789C71924100 @default.
• W4385667789 hasConceptScore W4385667789C86803240 @default.
• W4385667789 hasConceptScore W4385667789C88879693 @default.
• W4385667789 hasIssue "S3" @default.
• W4385667789 hasLocation W43856677891 @default.
• W4385667789 hasLocation W43856677892 @default.
• W4385667789 hasOpenAccess W4385667789 @default.
• W4385667789 hasPrimaryLocation W43856677891 @default.
• W4385667789 hasRelatedWork W1536174937 @default.
• W4385667789 hasRelatedWork W2097371321 @default.
• W4385667789 hasRelatedWork W2615902868 @default.
• W4385667789 hasRelatedWork W2889442370 @default.
• W4385667789 hasRelatedWork W2969232618 @default.
• W4385667789 hasRelatedWork W2979354104 @default.

• next